EQ vs. KRON, ALRN, EGRX, KZR, CARM, MURA, CKPT, MNOV, AEON, and CALC
Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Kronos Bio (KRON), Aileron Therapeutics (ALRN), Eagle Pharmaceuticals (EGRX), Kezar Life Sciences (KZR), Carisma Therapeutics (CARM), Mural Oncology (MURA), Checkpoint Therapeutics (CKPT), MediciNova (MNOV), AEON Biopharma (AEON), and CalciMedica (CALC). These companies are all part of the "pharmaceutical preparations" industry.
Equillium (NASDAQ:EQ) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Equillium currently has a consensus target price of $3.90, indicating a potential upside of 153.25%. Kronos Bio has a consensus target price of $4.13, indicating a potential upside of 320.49%. Given Kronos Bio's higher probable upside, analysts clearly believe Kronos Bio is more favorable than Equillium.
Equillium received 15 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 82.50% of users gave Equillium an outperform vote while only 66.67% of users gave Kronos Bio an outperform vote.
27.0% of Equillium shares are held by institutional investors. Comparatively, 64.1% of Kronos Bio shares are held by institutional investors. 30.3% of Equillium shares are held by insiders. Comparatively, 23.4% of Kronos Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Equillium had 1 more articles in the media than Kronos Bio. MarketBeat recorded 7 mentions for Equillium and 6 mentions for Kronos Bio. Equillium's average media sentiment score of 0.76 beat Kronos Bio's score of -0.11 indicating that Equillium is being referred to more favorably in the media.
Equillium has a net margin of -32.01% compared to Kronos Bio's net margin of -1,534.11%. Equillium's return on equity of -51.20% beat Kronos Bio's return on equity.
Equillium has higher revenue and earnings than Kronos Bio. Equillium is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.
Equillium has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.
Summary
Equillium beats Kronos Bio on 11 of the 16 factors compared between the two stocks.
Get Equillium News Delivered to You Automatically
Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Equillium Competitors List
Related Companies and Tools
